Drugline is a fortnightly electronic drug bulletin for health professionals.
Scroll

Drugline

Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.

Update on Influenza Vaccines

Drugline Volume 390

The Australian Technical Advisory Group on Immunisation (ATAGI) has released its advice for the administration of seasonal influenza vaccines in 2020. Influenza vaccines used in Australia this year will be quadrivalent and comprise two…

Read more

Generic Tiotropium Capsules

Drugline Volume 389

A generic tiotropium capsule has recently been added to the Pharmaceutical Benefits Scheme (PBS). Braltus® capsules are considered equivalent to Spiriva® capsules for the purposes of brand substitution on the PBS. However, some important…

Read more

Non-Steroidal Topical Therapy for Dermatitis

Drugline Volume 388

Topical corticosteroids have long been the mainstay of treatment for dermatitis that does not respond to moisturisers and emollients. Crisaborole is a new non-steroidal option approved for use in mild to moderate atopic dermatitis…

Read more

Updated PBS-listing for Pembrolizumab in treatment of metastatic non-small cell lung cancer

Drugline Volume 387

Pembrolizumab is now available on the Pharmaceutical Benefits Scheme (PBS) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) irrespective of programmed death ligand-1 (PD-L1) status. In the KEYNOTE-189 trial, pembrolizumab was used in…

Read more

Updated Oral and Dental Guidelines

Drugline Volume 386

An updated edition of the Therapeutic Guidelines: Oral and Dental has recently been released. This resource covers a broad range of conditions that are relevant to both dentists and medical practitioners. Some of the…

Read more

New Contraindications for Glaucoma Medication

Drugline Volume 385

New contraindications have been added to the product information of Ganfort® (bimatoprost + timolol). It is now advised that these eye drops not be used in patients with sino-atrial nodal block or second or…

Read more
Load More